Futu News reported on May 31 that “Pharmacomics” this Wednesday $CUTIA-B (02487.HK)$It was announced that the stock exchange will be held from May 31 to June 5. It is proposed to issue 21.2818 million shares, including a public sale of 2.1284 million shares (10%) and an international sale of 19.153,400 shares (90%). The issue price per share is HK$20.65-24.75, and 200 shares per lot. It is expected to be listed on June 12.
Company Overview
Kodi B is a dermatology-focused R&D biopharmaceutical company, focusing on a wide range of dermatology treatment and care treatment fields, including localized fat accumulation management drugs, hair diseases and care, skin diseases and care, and epidermal anesthesia. The company has one core product and eight other pipeline candidate products, and also distributes two commercial products developed by overseas partners. The core product CU-20401 (a recombinant mutant collagen enzyme that targets obesity, overweight, or other metabolic diseases associated with localized fat accumulation) was developed as a local fat accumulation management drug for skin disease treatment, while the local fat accumulation management drug market in China is still in the early stages of growth, and there are no approved products yet. As of the last practical date, the company held a patent relating to the core product.
The Kodi Group was founded by Tonghe Yucheng and Zhang Lele. It is a “pharmacology” company. Among them, Yucheng Capital is an investment company that became independent from Pharmaceutical Kangde's venture capital department...